Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.

Sci Rep · 2026 · PMC12948971 · PMID 41654611

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The frequency of CD8 + T cells in lymphocytes showed no significant correlation with BoR at baseline, while its trajectory also presented a decreasing trend following camrelizumab administration (Supplementary Appendix Figure S9).

also in 47,180 other papers

did not reach statistical significanceno p-value reported

This numerical difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.